Translational research in pediatric pulmonary disease, 2017 by unknown
Rubin  Clin Trans Med  (2017) 6:12 
DOI 10.1186/s40169-017-0142-9
PERSPECTIVE




As readers of this journal know, translational research is the application of basic science findings to improve clini-
cal care; a process that was once called “bench-to-bedside” research. In my field of pediatric pulmonary disease, the 
rapid advancement of basic science understanding into improved clinical care has been, to use an appropriate term, 
breathtaking. In this perspective article, I will describe a few of these advances, as they relate to specific pulmonary 
diseases.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
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Background
As readers of this journal know, translational research 
is the application of basic science findings to improve 
clinical care; a process that was once called “bench-to-
bedside” research. In my field of pediatric pulmonary 
disease, the rapid advancement of basic science under-
standing into improved clinical care has been, to use an 
appropriate term, breathtaking. In this perspective arti-
cle, I will describe a few of these advances, as they relate 
to specific pulmonary diseases.
Cystic fibrosis (CF)
In many ways, therapeutic development for CF can be con-
sidered a paradigm for translational research. Improved 
understanding of the CF transmembrane ion regulator 
(CFTR) protein function has led to the development of 
orally available, small molecule CFTR potentiators and 
correctors that have dramatically transformed our under-
standing and care of this disease. The CFTR potentiator, 
ivacaftor, is the closest that we have come to a “cure” for 
CF for those patients with class 3, gating CFTR mutations 
[1]. The combination of ivacaftor and the CFTR corrector, 
lumacaftor, can decrease the frequency of pulmonary exac-
erbations in patients with the most common Phe508del, 
class 2 mutation [2]. There are now many CFTR gene and 
protein specific therapies being investigated by commer-
cial and academic institutions, in pre-clinical and in more 
advanced clinical trials. There is also significant interest to 
see if improving the function of CFTR might affect other 
airway diseases that are associated with airway inflamma-
tion, such as chronic bronchitis.
It is extremely likely that gene editing techniques, such 
as the CRISPR/Cas9 system, will be first be used to treat 
diseases like CF or neuromuscular diseases that are asso-
ciated with single gene abnormalities.
Asthma
In recent years, we have seen the introduction of biologic 
therapies for the treatment of severe asthma in older chil-
dren and adults. These are principally directed at the eosin-
ophilic or TH2 dominant phenotype. There is rich and 
diverse pipeline of biologics being investigated for improved 
asthma management [3], and even for the potential pre-
vention of asthma in children with asthma predisposition. 
Although early intervention with environmental control 
has not proven to be as effective in preventing asthma, our 
understanding of early exposure to infections and allergens 
and how these interact with the child’s genome and gene 
expression (through epigenetic modification) is giving us a 
much richer picture of asthma endotypes and to possibly 
identify children at risk of developing asthma, and how this 
risk could potentially be modified.
There are intriguing studies underway evaluating alter-
ations of the microbiome, the early immune response, 
and the interaction between allergens and respiratory 
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viruses to determine if these research applications can 
successfully be used to treat or prevent the development 
of this chronic airway disease [4].
Neuromuscular disease and respiratory compromise
Translational research in patients with neuromuscular 
disorders has focused on developing drugs that modify 
the expression of genes associated with diseases such 
as spinal motor atrophy and muscular dystrophy. Medi-
cations like ataluren, a premature termination codon, 
“read-through” medication, appear to be effective disease 
modifiers in some of these disorders [5].
Plastic bronchitis and pulmonary lymphatics
One of the most exciting advances in pediatric pulmo-
nary medicine is recognizing that the pulmonary lym-
phatics play an important role in the development of 
pulmonary disease. Plastic bronchitis is a syndrome 
where the airways fill with firm, cohesive material that 
can completely obstruct. It is most common in children 
with congenital heart disease and single ventricle physi-
ology, although only a small minority of children with 
single ventricle physiology will develop plastic bronchitis 
[6]. Innovative work by Dori and Itkin, out of Philadel-
phia, has demonstrated that the children who develop 
plastic bronchitis with congenital heart disease, have 
aberrant lymphatic drainage to the thoracic duct, and 
that this aberrant drainage can be corrected by lymphatic 
intervention, gluing shut the abnormal vessels [7]. In 
almost all patients that are so treated, this has been life 
changing. Interest in the role of pulmonary lymphatics 
has also led to novel discoveries as to how this “third” cir-
culatory system, in the lungs, can affect diseases such as 
chronic lung disease of the newborn.
Childhood interstitial lung diseases (chILD)
The interstitial lung diseases of childhood, so called chILD, 
until fairly recently were classified based upon histologic 
appearance and clinical outcomes and although these met-
rics are still useful; identification of the genetic causes of 
many of these diseases is making classification more precise 
and helping to identify potential therapeutic targets. Moreo-
ver, in the case of surfactant metabolism disorders of the 
neonate and infant, what were once considered histologi-
cally distinctly disorders, e.g. pulmonary alveolar proteinosis 
(PAP), nonspecific interstitial pneumonitis, diffuse intersti-
tial pneumonitis, and chronic pneumonitis of infancy are 
now recognized to have related underlying genetic mecha-
nisms making it possible to identify some patients with these 
disorders by genetic testing rather than by lung biopsy [8].
Using PAP as an example, it is now recognized that 
the severe, neonatal form is caused by deficiency in the 
hydrophobic surfactant apoprotein (Sp)B. Abnormalities 
in the adenosine binding cassette subtype A3 (a phos-
pholipid transporter) can also cause PAP and abnormali-
ties in SpC can cause later onset ILD in the child and in 
adulthood. The more common, but still quite rare adult 
onset form of PAP is usually caused by autoantibodies 
to the granulocyte–macrophage colony stimulating fac-
tor (GM-CSF) essential for maturation of alveolar mac-
rophages; the cell responsible for surfactant recycling in 
the acinus. Understanding the key role of GM-CSF in 
surfactant metabolism permitted the identification of a 
juvenile onset PAP caused by abnormalities in the GM-
CSF receptor [9]. This, in turn, has allowed the develop-
ment of novel therapies for these serious diseases.
This is a brief overview of how basic research is being 
rapidly applied to dramatically transform the clinical care 
of children with pulmonary disease. With tools that allow 
us to better understand the role of the genome, bio-infor-
matics for managing massive databases, better phenotyp-
ing and genotyping of diseases, and an understanding of 
how social and environment influences can alter the epi-
genetic expression of genes and proteins we are likely to 
see dramatic advances in clinical care in the next decade.
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